<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The International Workshop on the relationship between prior therapy and balanced chromosome aberrations in therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and therapy-related <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (t-AL) identified 79 of 511 (15.5%) patients with balanced 21q22 translocations </plain></SENT>
<SENT sid="1" pm="."><plain>Patients were treated for their <z:e sem="disease" ids="C0277554" disease_type="Disease or Syndrome" abbrv="">primary disease</z:e>, including <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> (56%), <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancy</z:e> (43%), and <z:hpo ids='HP_0005681'>juvenile rheumatoid arthritis</z:hpo> (single case), by radiation therapy (5 patients), chemotherapy (36 patients), or combined-modality therapy (38 patients) </plain></SENT>
<SENT sid="2" pm="."><plain>21q translocations involved common partner chromosomes in 81% of cases: t(8;21) (n = 44; 56%), t(3;21) (n = 16; 20%), and t(16;21) (n = 4; 5%) </plain></SENT>
<SENT sid="3" pm="."><plain>Translocations involving 15 other partner chromosomes were also documented with involvement of AML1(CBFA2/RUNX1), identifying a total of 23 different 21q22/AML1 translocations </plain></SENT>
<SENT sid="4" pm="."><plain>The data analysis was carried out on the basis of five subsets of 21q22 cases, that is, t(8;21) with and without additional aberrations, t(3;21), t(16;21), and other 21q22 translocations </plain></SENT>
<SENT sid="5" pm="."><plain>Dysplastic features were present in <z:hpo ids='HP_0000001'>all</z:hpo> 21q22 cases </plain></SENT>
<SENT sid="6" pm="."><plain>Therapy-related <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) at presentation was highest in t(8;21) (82%) and lowest in t(3;21) (37.5%) patients </plain></SENT>
<SENT sid="7" pm="."><plain>Cumulative drug dose exposure scores for <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> (AAs) and <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi> indicated that t(3;21) patients received the most intensive therapy among the five 21q22 subsets, and the median AA score for patients with secondary chromosome 7 aberrations was double the AA score for the entire 21q22 group </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> five patients who received only radiation therapy had t(8;21) t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The median latency and overall survival (OS) for 21q22 patients were 39 and 14 months (mo), compared to 26 and 8 mo for 11q23 patients, 22 and 28 mo for inv(16), 69 and 7 mo for Rare recurring aberrations, and 59 and 7 mo for Unique (nonrecurring) balanced aberration (latency P &lt; or = 0.016 for <z:hpo ids='HP_0000001'>all</z:hpo> pairwise comparisons; OS, P &lt; or = 0.018 for <z:hpo ids='HP_0000001'>all</z:hpo> pairwise comparisons) </plain></SENT>
<SENT sid="10" pm="."><plain>The percentages of 21q22 patients surviving 1 year, 2 years, and 5 years were 58%, 33%, and 18%, respectively </plain></SENT>
<SENT sid="11" pm="."><plain>Noticeable differences were observed in median OS between 21q22 patients (n = 7) receiving transplant (BMT) (31 mo) compared to 21q22 patients who received intensive non-BMT therapy (n = 46) (17 mo); however, this was nonsignificant because of the small sample size (log-rank, P = 0.33) </plain></SENT>
<SENT sid="12" pm="."><plain>t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with balanced 21q22 aberrations was associated with prior exposure to radiation, epipodophyllotoxins, and <z:chebi fb="0" ids="48120">anthracyclines</z:chebi>, dysplastic morphologic features, multiple partner chromosomes, and longer latency periods when compared to 11q23 and inv(16) t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> Workshop subgroups </plain></SENT>
<SENT sid="13" pm="."><plain>In general, patients could be divided into two prognostic risk groups, those with t(8;21) (median OS, 19 mo) and those without t(8;21) (median OS, 7 mo) <z:hpo ids='HP_0001909'>leukemia</z:hpo> (log-rank, P = 0.0007) </plain></SENT>
</text></document>